Skip to main content
NCBI home page
Brain Pathology logoLink to Brain Pathology
. 2006 Apr 5;13(2):133–143. doi: 10.1111/j.1750-3639.2003.tb00013.x

Vascular Patterns in Glioblastoma Influence Clinical Outcome and Associate with Variable Expression of Angiogenic Proteins: Evidence for Distinct Angiogenic Subtypes

Peter Birner 1,2, Maria Piribauer 3, Ingeborg Fischer 2, Brigitte Gatterbauer 4, Christine Marosi 3, Peter F Ambros 5, Inge M Ambros 5, Markus Bredel 2,*, Georg Oberhuber 1, Karl Rössler 4, Herbert Budka 2, Adrian L Harris 6, Johannes A Hainfellner 2,✉
PMCID: PMC8095831  PMID: 12744467

Abstract

No data exist on angiogenic patterns and their prognostic impact in human glioblastoma. Such data are relevant for translation of antiangiogenic therapies into clinical applications. Using immunohistochemistry for CD34, we assessed vascular patterns in 114 primary glioblastomas. Vascular patterns comprised unevenly distributed glomeruloid/garland‐like/clustered bizarre vascular formations and evenly distributed delicate capillary‐like microvessels (“classic” vascular pattern). The combination of low content of bizarre vascular formations and prominent classic vascular pattern (n=29) was an independent factor for longer survival (p= 0.006, Cox regression), as well as postoperative high Karnofsky performance status (p=0.005). In patients with a prominent classic vascular pattern, there was no difference of MIB1 labeling index whereas microvessel density and apoptotic index (TUNEL) were significantly higher as compared to all other patients (p<0.05). In addition, diffuse expression of hypoxia‐inducible factor (HIF)‐1α and strong expression of vascular endothelial growth factor were more common (p<0.05, Chi‐square test). FISH revealed loss of chromosomes 1p and 19q only in 1/7 long‐time survivors with classic pattern. We conclude that vascular patterns in primary glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins. Our findings denote for the first time distinct angiogenic subtypes of human glioblastoma which may prove relevant for anti‐angiogenic therapy approaches.

Full Text

The Full Text of this article is available as a PDF (645.3 KB).

References

  • 1. Ambros PF, Ambros IM (2001) Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 37:492–504. [DOI] [PubMed] [Google Scholar]
  • 2. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM (1998) Stabilization of wild‐type p53 by hypoxia‐inducible factor 1a. Nature 392:405–408. [DOI] [PubMed] [Google Scholar]
  • 3. Bernsen HJ, Rijken P, Hagemeier NE, van der Kogel AJ (1999) Aquantitative analysis of vascularization and perfusion of human glioma xenografts at different implantation sites. Microvasc Res 57:244–257. [DOI] [PubMed] [Google Scholar]
  • 4. Birner P, Gatterbauer B, Oberhuber G, Schindl M, Rössler K, Prodinger A, Budka H, Hainfellner JA (2001) Expression of hypoxia‐inducible factor 1a in oligoden‐drogliomas: its impact on prognosis and on neoangio‐genesis. Cancer 92:165–171. [DOI] [PubMed] [Google Scholar]
  • 5. Birner P, Piribauer M, Fischer I, Gatterbauer B, Marosi C, Ungersböck K, Rössler K, Budka H, Hainfellner J (2002) Prognostic relevance of p53 protein expression in glioblastoma. Oncol Rep 9:703–707. [PubMed] [Google Scholar]
  • 6. Birner P, Schindl M, Obermair A, Breitenecker G, Ober‐huber G (2001) Expression of hypoxia‐inducible factor (HIF) 1a in epithelial ovarian tumors: Its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7:1661–1668. [PubMed] [Google Scholar]
  • 7. Bos R, Zhong H, Hanrahan C, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E (2001) Levels of hypoxia‐inducible factor‐1a during breast carcinogenesis. J Natl Cancer Inst 93:309–314. [DOI] [PubMed] [Google Scholar]
  • 8. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshert E (1998) Role of HIF‐1alpha in hypoxia mediated apoptosis, cell proliferation and tumor angio‐genesis. Nature 394:485–490. [DOI] [PubMed] [Google Scholar]
  • 9. Cooke HJ, Hindley J (1979) Cloning of human satellite III DNA: different components are on different chromosomes. Nucleic Acids Research 6:3177–3197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Dang CV, Semenza GL (1999) Oncogenic alterations of metabolism. Trends Biochem Sci 24:68–72. [DOI] [PubMed] [Google Scholar]
  • 11. Ding H, Roncari L, Shannon P, Wu X, Lau N, Karaskova J, Gutmann D, Squire J, Nagy A, Guha A (2001) Astrocyte‐specific expression of activated p21‐ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res 61:3826–3836. [PubMed] [Google Scholar]
  • 12. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK (2000) Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high‐grade gliomas. J Clin Oncol 18:708–715. [DOI] [PubMed] [Google Scholar]
  • 13. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer‐Rachamimov AO, Ramsay DA, Cairncross JG, Louis DN (2001) Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 7:839–845. [PubMed] [Google Scholar]
  • 14. Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, Gassmann M, Gearhart JD, Lawler AM, Yu AY, Semenza GL (1998) Cellular and developmental control of O2 homeostasis by hypoxia‐inducible factor 1a. Genes Dev 12:149–162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Kaplan EL, Meier P (1985) Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481. [Google Scholar]
  • 16. Karnofsky DA. (1972) Criteria of performance status (P. S.) In: Hematology, Williams W.J., Beutler E., Erslev A.J. and Rundles R.W. (eds.) p. 4, McGraw‐Hill: New York . [Google Scholar]
  • 17. Kleihues P, Burger PC, Collins VP, Newcomb EW, Ohgaki H Cavenee WK. (2000) Glioblastoma In: Pathology and genetics of tumors of the nervous system, Kleihues P. and Cavenee W.K. (eds.) pp. 29–39. IARC Press: Lyon . [Google Scholar]
  • 18. Korhunov A, Golanov A, Sycheva R, Pronin I (1999) Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblas‐tomas: an analysis of 168 cases. J Clin Pathol 52:574–580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. König J, Tolnay E, Wiethege T, Müller K (1999) Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma. Virchows Arch 435:8–12. [DOI] [PubMed] [Google Scholar]
  • 20. Kruger EA, Blagosklonny MV, Dixon SC, Figg WD (1998) UCN‐01, a proteinkinase C inhibitor, inhibits endothelial cell proliferation and angiogenic response. Invasion Metastasis 18:209–218. [DOI] [PubMed] [Google Scholar]
  • 21. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM, Bundred N (1999) Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 59:856–861. [PubMed] [Google Scholar]
  • 22. Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM (2000) Suppression of tumor growth through disruption of hypoxia‐inducible transcription. Nature Med 6:1335–1340. [DOI] [PubMed] [Google Scholar]
  • 23. Lund EL, Spang‐Thomsen M, Skovgaard‐Poulsen H, Kristjansen PE (1998) Tumor angiogenesis‐a new therapeutic target in gliomas. Acta Neurol Scand 97:52–56. [DOI] [PubMed] [Google Scholar]
  • 24. Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O'Relly R, Bader BL, Hynes RO, Zhuang Y, Manova K, Benezra R (1999) Id1 and Id3 are required for neurogensis, angio‐genesis and vascularization of tumour xenografts. Nature 401:670–677. [DOI] [PubMed] [Google Scholar]
  • 25. Maxwell PH, Wiesener MS, Chang G, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1999) The tumor suppressor protein VHL targets hypoxia‐inducable factors for oxygen‐dependent prote‐olysis. Nature 399:271–276. [DOI] [PubMed] [Google Scholar]
  • 26. Melillo G, Sausville EA, Cloud K, Lahusen T, Varesio L, Senderowicz AM (1999) Flavopiridol, a protein kinase inhibitor, down‐regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res 59:5433–5437. [PubMed] [Google Scholar]
  • 27. O'Rourke JF, Tian YM, Ratcliffe PJ, Pugh CW (1999) Oxygen‐regulated and transactivating domains in endothelial PAS protein 1: comparison with hypoxia‐inducible factor‐1a. J Biol Chem 274:2060–2071. [DOI] [PubMed] [Google Scholar]
  • 28. Plate KH (1996) Gene therapy of malignant glioma via inhibition of tumor angiogenesis. Cancer Metast Rev 15:237–240. [DOI] [PubMed] [Google Scholar]
  • 29. Ryan HE, Lo J, Johnson RS (1998) HIF‐1a is required for solid tumor formation and embryonic vascularization. EMBO J 17:3005–3015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit J, Johnson RS (2000) Hypoxia‐inducible factor‐1a is a positive factor in solid tumor growth. Cancer Res 60:4010–4015. [PubMed] [Google Scholar]
  • 31. Schiffer D. (1993) Blood vessel architecture and angiogenesis in gliomas In: Brain tumors: pathology and its biological correlates, Schiffer D. (ed.) pp. 148–152. Springer Verlag: Berlin . [Google Scholar]
  • 32. Schindl M, Birner P, Obermair A, Kiesel L, Wenzl R (2001) Increased microvessel density in adenomyosis uteri. Fertil Steril 75:131–135. [DOI] [PubMed] [Google Scholar]
  • 33. Schindl M, Oberhuber G, Obermair A, Schoppmann SF, Karner B, Birner P (2001) Overexpression of Id‐1 protein is a marker for unfavorable prognosis in early‐stage cervical cancer. Cancer Res 61:5703–5706. [PubMed] [Google Scholar]
  • 34. Schmidt MC, Antweiler S, Urban N, Müller W, Kuklik A, Meyer‐Puttlitz B, Wiestler OD, Louis DN, Fimmer R, von Deimling A (2002) Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 61:321–328. [DOI] [PubMed] [Google Scholar]
  • 35. Semenza GL (1999) Regulation of mammalian O2 homeostasis by hypoxia‐inducible factor 1. Annu Rev Cell Dev Biol 15:551–578. [DOI] [PubMed] [Google Scholar]
  • 36. Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger MS, Godfrey T, Nigro J, Prado M, Chang S, Barker F, Aldape K (2001) Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 61:1122–1128. [PubMed] [Google Scholar]
  • 37. Stratmann A, Machein M, Plate KH (1997) Anti‐angiogenic gene therapy of malignant glioma. Acta Neurochir Suppl (Wien) 68:105–110. [DOI] [PubMed] [Google Scholar]
  • 38. Sun X, Kanwar JR, Leung E, Lehnert K, Wand D, Krissansen GW (2001) Gene transfer of antisense hypoxia inducible factor‐1 alpha enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther 8:638–645. [DOI] [PubMed] [Google Scholar]
  • 39. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL (2000) The expression and distribution of the hypoxia‐inducible factors HIF‐1a and HIF‐2a in normal human tissues, cancers, and tumor associated macrophages. Am J Pathol 157:411–421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Theurillat J, Hainfellner J, Maddalena A, Weissenberger J, Aguzzi A (1999) Early induction of angiogenic signals in gliomas of GFAP‐v‐src transgenic mice. Am J Pathol 154:581–590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Weidner N (1995) Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36:169–180. [DOI] [PubMed] [Google Scholar]
  • 42. Wesseling P, van der Laak JA, Link M, Teepen HL, Ruiter DJ (1998) Quantitative analysis of microvascular changes in diffuse astrocytic neoplasms with increasing grade of malignancy. Hum Pathol 29:352–358. [DOI] [PubMed] [Google Scholar]
  • 43. Wiesener MS, Turley H, Allen WE, Willam C, Eckardt KU, Talks KL, Wood SM, Gatter KC, Harris AL, Pugh CW, Ratcliffe PJ, Maxwell PH (1998) Induction of endothelial PAS domain protein‐1 by hypoxia: characterization and comparison with hypoxia‐inducible factor‐1a. Blood 92:2260–2268. [PubMed] [Google Scholar]
  • 44. Xu L, Fidler IJ (2000) Acidic pH‐induced elevation in interleukin 8 expression by human ovarian carcinoma cells. Cancer Res 60:4610–4616. [PubMed] [Google Scholar]
  • 45. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL (2000) Expression of hypoxia‐inducible factor 1a in brain tumors. Association with angiogenesis, invasion, and progression. Cancer 88:2606–2618. [PubMed] [Google Scholar]
  • 46. Zhong H, Agani F, Baccala AA, Laughner E, Rioseco‐Camacho N, Isaacs WB, Simons JW, Semenza GL (1998) Increased expression of hypoxia inducable factor‐1a in rat and human prostate cancer. Cancer Res 58:5280–5284. [PubMed] [Google Scholar]
  • 47. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL (2000) Modulation of hypoxia‐inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3‐kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541–1545. [PubMed] [Google Scholar]
  • 48. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton D, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW (1999) Overexpression of hypoxia‐inducable factor 1a in common human cancers and their metastases. Cancer Res 59:5830–5835. [PubMed] [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES